Asenapine 5 and 10 mg bid was generally safe and well tolerated up to 29 weeks.
The metabolic effects of ASN appear consistent with previous studies.
No dose dependence for predefined treatment-emergent adverse events.
Serious adverse events primarily due to underlying bipolar I disorder.